XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Note 13 - Segment Information
 9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

13.    Segment Information

 

The Company follows ASC 280, “Segment Reporting,” which establishes standards for companies to report information about operating segments, geographic areas and major customers. The accounting policies of each reportable segment are the same as those described in the summary of significant accounting policies (see Note 1 to the Company’s Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2022).

 

Segment operating income includes selling, general and administrative expenses directly attributable to that segment as well as charges for allocating corporate costs to each of the operating segments. The following tables reflect the results of the reportable segments consistent with the Company’s management system:

 

Thirteen Weeks Ended

September 30, 2023

 

Specialty

Health Care

  

Engineering

  

Life Sciences

and IT

  

Corporate

  

Total

 

Revenue

 $24,895  $22,452  $10,702  $-  $58,049 

Cost of services

  17,438   16,846   6,484   -   40,768 

Gross profit

  7,457   5,606   4,218   -   17,281 

Selling, general and administrative

  5,977   4,327   2,358   -   12,662 

Depreciation and amortization of

property and equipment

  88   122   33   -   243 

Amortization of acquired

intangible assets

  -   -   45   -   45 

Operating income

  1,392   1,157   1,782  $-  $4,331 

Total assets as of September 30, 2023

 $32,272  $45,949  $17,662  $5,331  $101,214 

Property and equipment acquired

 $62  $162  $69  $22  $315 

 

 

Thirteen Weeks Ended

October 1, 2022

 

Specialty

Health Care

  

Engineering

  

Life Sciences

and IT

  

Corporate

  

Total

 

Revenue

 $27,997  $20,922  $9,233  $-  $58,152 

Cost of services

  19,014   15,594   6,186   -   40,794 

Gross profit

  8,983   5,328   3,047   -   17,358 

Selling, general and administrative

  5,933   4,531   2,087   -   12,551 

Depreciation and amortization of

property and equipment

  101   136   29   -   266 

Gain on sale of assets

  -   (219

)

  -   -   (219

)

Operating income

 $2,949  $880  $931  $-   4,760 

Total assets as of October 1, 2022

 $33,280  $32,343  $8,579  $2,607  $76,809 

Capital expenditures

 $9  $207  $39  $266  $521 

 

 

Thirty-Nine Weeks Ended

September 30, 2023

 

Specialty

Health Care

  

Engineering

  

Life Sciences and IT

  

Corporate

  

Total

 

Revenue

 $99,553  $61,956  $30,700  $-  $192,209 

Cost of services

  70,623   47,482   19,039   -   137,144 

Gross profit

  28,930   14,474   11,661   -   55,065 

Selling, general and administrative

  19,211   12,626   6,945   -   38,782 

Depreciation and amortization of

property and equipment

  281   370   105   -   756 

Amortization of acquired

intangible assets

  -   -   136   -   136 

Gain on sale of assets

  -   (395

)

  -  $-   (395

)

Operating income

  9,438   1,873   4,475      15,786 

Total assets as of September 30, 2023

 $32,272  $45,949  $17,662  $5,331  $101,214 

Property and equipment acquired

 $109  $640  $88  $38  $875 

 

 

Thirty-Nine Weeks Ended

October 1, 2022

 

Specialty Health Care

  

Engineering

  

Life Sciences and IT

  

Corporate

  

Total

 

Revenue

 $123,638  $61,726  $29,095  $-  $214,459 

Cost of services

  86,772   45,653   19,573   -   151,998 

Gross profit

  36,866   16,073   9,522   -   62,461 

Selling, general and administrative

  21,203   12,659   6,100   -   39,962 

Depreciation and amortization of

property and equipment

  322   332   75   -   729 

Gain on sale of assets

  -   (219

)

  -   -   (219

)

Operating income

 $15,341  $3,301  $3,347  $-  $21,989 

Total assets as of October 1, 2022

 $33,280  $32,343  $8,579  $2,607  $76,809 

Capital expenditures

 $57  $496  $102  $275  $930 

 

The Company derives a majority of its revenue from offices in the United States. Revenues reported for each operating segment are all from external customers. The Company is domiciled in the United States and its segments operate in the United States, Canada, Puerto Rico and Europe. Revenue by geographic area for the thirteen and thirty-nine weeks ended September 30, 2023 and October 1, 2022 was as follows:

 

 

Thirteen Weeks Ended

  

Thirty-Nine Weeks Ended

 
 

September 30,

2023

  

October 1,

2022

  

September 30,

2023

  

October 1,

2022

 

Revenue

               

United States

$53,679  $55,180  $179,800  $205,162 

Canada

 1,647   1,091   5,060   3,555 

Puerto Rico

 1,643   1,261   4,745   3,760 

Europe

 1,080   620   2,604   1,982 
 $58,049  $58,152  $192,209  $214,459 

 

Total assets by geographic area as of the reported periods were as follows:

 

 

September 30,

2023

  

December 31,

2022

 

Total assets

       

United States

$91,141  $81,558 

Canada

 1,829   1,640 

Puerto Rico

 4,157   1,401 

Europe

 4,087   3,365 
 $101,214  $87,964